Bionano genomics news.

4 Agu 2023 ... Bionano Genomics, Inc. (BNGO) will effect a one-for-ten (1-10) ... Nasdaq offers customers the ability to self select news delivery across various ...BNGO: Get the latest Bionano Genomics stock price and detailed information including BNGO news, historical charts and realtime prices. Indices Commodities Currencies StocksSAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it has entered into a definitive agreement to acquire BioDiscovery, Inc., a leading software company ...Bionano Announces Results from its Annual Meeting of Stockholders. SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that its stockholders approved all proposals set forth at its 2023 Annual Meeting, held earlier today. The final voting results will be available in a current report on Form 8-K, which ...Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform ...

News Release Details « Back. Bionano Genomics Reports Second Quarter 2022 Financial Results and Highlights Recent Business Progress. Aug 04, 2022 | PDF Version - 73% year-over-year revenue growth in Q2 2022 - Achieved all 1H 2022 ELEVATE! milestones - Strong balance sheet with $187.3 million in cash, cash equivalents, and …Bionano Genomics shares will start to get out of their current rut. It’ll start breaking out of its current $5-$6 per share trading range. After that, it’ll be up to other factors to help fuel ...

Bionano Genomics: PB2245: A combination of exome sequencing and optical genome mapping unveils a dual molecular diagnosis in a case with an unknown neurodevelopmental disorder Acharya A. Columbia University: PB2261: B-allele frequency-based approach to detecting absence of heterozygosity using optical genome mapping …

SAN DIEGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese OEM partner, Ecobono, a distribution company focused on reproductive health products, has obtained reagent Class I registration from China's NMPA for Bionano's DNA isolation products. Ecobono is Bionano’s third Chinese OEM ...Over the past 30 days, the shares of Bionano Genomics Inc (NASDAQ:BNGO) have changed 24.81%. Short interest in the company has seen 7.08 million shares shorted with days to cover at 6.06. Wall Street analysts have a consensus price target for the stock at $12.33, which means that the shares’ value could jump …The average price point forecasted by analysts for Bionano Genomics Inc (BNGO) is $12.33, which is $10.7 above the current market price. The public float for BNGO is 38.09M, and currently, short sellers hold a 17.35% ratio of that float. The average trading volume of BNGO on November 27, 2023 was 888.80K shares. Top 5 EV Tech Stocks to Buy for ...Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine.A big change in the C-suite was behind the steep fall in Bionano Genomics ' ( BNGO -7.27%) share price on Monday. Following the biotech's announcement that its CFO is stepping down, investors ...

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of …

NEW YORK – Bionano Genomics' Chinese original equipment manufacturing (OEM) partner, Beijing Genome Precision Technology (BGPT), has obtained reagent class I registrations from China's National Medical Products Administration (NMPA) for Bionano's DNA extraction kit and labeling products, GenomeWeb has learned. At …

Mar 31, 2022 · SAN DIEGEO, May 05, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr ® system and provider of NxClinical™ software, a leading solution for visualization, interpretation and reporting of genomic data, today reported financial results for the first quarter ended ... Mar 31, 2022 · UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates. Preliminary Q1 total revenue expected to be between $7.3 and $7.5 million, which would represent an estimated increase of 28% to 32% over Q1 2022. Installed base of Saphyr® systems reached 259 as of March 31, 2023, which represents growth of the installed base by 19 ... The market expects Bionano Genomics, Inc. (BNGO) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022.BNGO Stock 12 Months Forecast. $6.33. (298.11% Upside) Based on 3 Wall Street analysts offering 12 month price targets for BioNano Genomics in the last 3 months. The average price target is $6.33 with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 298.11% change from the last price of $1.59.The average price point forecasted by analysts for Bionano Genomics Inc (BNGO) is $12.33, which is $10.7 above the current market price. The public float for BNGO is 38.09M, and currently, short sellers hold a 17.35% ratio of that float. The average trading volume of BNGO on November 27, 2023 was 888.80K shares. Top 5 EV Tech Stocks to Buy for ...Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume ... Bionano Genomics, Inc. +1 (858) 888-7610 [email protected]. Investor ...

About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.About Bionano Genomics Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business ...Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ...Based on BioNano Genomics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $7.22 million and a GAAP net loss of $31.81 million.For the last reported quarter, it was expected that Bionano Genomics, Inc. Would post a loss of $0.90 per share when it actually produced a loss of $1.24, delivering a surprise of -37.78%.In a single enzymatic reaction, the Bionano Direct Label and Stain (DLS) workflow recognizes a 6 bp sequence motif occurring approximately 14-17 times per 100 kbp in the human genome and transfers a fluorescent label to it via covalent modification. This labeling step results in a uniquely identifiable sequence-specific pattern of labels to be used for …

Aug 1, 2023 · SAN DIEGO , Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-10. The effective time of the reverse stock split will be 5 p.m. ET on August 4, 2023. Nov 28, 2022 · About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Bionano Genomics. May 9, 2023 at 4:01 PM · 17 min read. Bionano Genomics. Q1 2023 revenue was $7.4 million, which represents a 30% increase over Q1 2022. Installed base of 259 Saphyr® systems ...BNGO | Complete Bionano Genomics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the Association for Molecular Pathology (AMP) 2023 Annual Meeting and Expo ...Mar 9, 2023 · Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. BioNano Genomics News & Media. Bionano Genomics, Inc. (BNGO) Presents at Stifel Healthcare Conference (Transcript) Bionano Genomics, Inc. (NASDAQ:NASDAQ:BNGO) Stifel Healthcare Conference Call November 15, 2023 1:50 PM ETCompany ParticipantsErik Holmlin - CEOConference... Nov 15, 2023. seekingalpha.com . Bionano Announces …Aug 4, 2023 · SAN DIEGO, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO) today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ...

Bionano’s Stratys system for OGM offers increased throughput capabilities to address the needs of mid and high-volume users. The throughput of the Stratys instrument is up to four times greater than that of Bionano’s Saphyr instrument, it is compatible with the latest G2 chemistry and has a potential sample-to-answer time of 3 days for ...

SAN DIEGO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the pricing of (i) $45.0 million aggregate principal amount of senior secured convertible notes ...

Bionano Genomics Q3 Revenues Grow 29 Percent. In line with its previous estimate, the San Diego-based optical genome mapping company reported $9.3 million in revenues, compared to $7.2 million a year ago.Apr 13, 2023 · About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Aug 9, 2023 · Nov 3, 2022 at 4:30 PM EDT. Sep 12, 2022 at 7:00 AM EDT. 2022 Maxim Virtual Growth Conference. Mar 15, 2022 at 8:40 AM EDT. Please click HERE to join. Mar 9, 2022 at 2:10 PM EST. 42nd Annual Cowen Healthcare Conference. Please click HERE to join. Mar 1, 2022 at 4:30 PM EST. In 2022, BNGO's revenue was $27.80 million, an increase of 54.62% compared to the previous year's $17.98 million. Losses were -$132.60 million, 83.1% more than in 2021. According to 4 analysts, the average rating for BNGO stock is "Buy." The 12-month stock price forecast is $46.67, which is an increase of 2,853.80% from the latest …SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first peer-reviewed benchmarking study …Bionano Genomics sees Q3 net loss widen 53% but beats on the top line SA News Thu, Nov. 03, 2022 Bionano Genomics net loss of $31.81M, revenue of …Latest BioNano Genomics Inc Stock News. As of November 24, 2023, BioNano Genomics Inc had a $56.3 million market capitalization, putting it in the 30th percentile of companies in the Advanced Medical Equipment & Technology industry. BioNano Genomics Inc does not have a meaningful P/E due to negative earnings over …Track Bionano Genomics Inc (BNGO) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAbout Bionano Genomics Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software.

Apr 13, 2023 · About Bionano Genomics. Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. Aug 14, 2023 · SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Aug 14, 2023 · SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Gülsen Kama will serve as its next Chief Financial Officer (CFO), effective September 11, 2023. Christopher Stewart, who held the position of CFO since September 2020, will stay on during the transition and then move into an advisory role. Bionano Genomics (BNGO) has announced that Gülsen Kama will serve as its next CFO, effective September 11, 2023.Christopher Stewart, who held the position of CFO since September 2020,...Instagram:https://instagram. first horizon national corporation stocknasdaq portfoliois first trade goodthe best funded trader program Bionano's second strategic pillar is to "delight our customers with robust products that are suitable for routine use at scale," he said. In addition to building a strong field support team, Bionano has a number of planned product updates, which include updates to the company's DNA isolation and labeling chemistries as well as integrating OGM ...SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). best banks in illinoischristmas stocks Nov 30, 2023 · SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the publication by scientists at Revvity Omics (formerly Perkin Elmer Genomics), Leiden University Medical Centre, Bombay Hospital, and UT Dallas, of the largest peer-reviewed study to date on the use of optical genome mapping (OGM) to diagnose facioscapulohumeral muscular dystrophy (FSHD). Bionano Genomics, Inc. +1 (858) 888-7610. [email protected]. Investor Relations: Amy Conrad. Juniper Point. +1 (858) 366-3243. [email protected]. Bionano CEO and president Dr. Erik Holmlin ... pvc prices SAN DIEGO, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Cancer Genomics Consortium (CGC) 2023 Annual Meeting with a broad range of content covering the utility of optical genome mapping (OGM) for solid tumor and hematological malignancy cancer research, including scientific …11 Jan 2023 ... Bionano Genomics (BNGO) is trending after announcing a publication showing that genome mapping can help in identifying breast cancer.News Release Details « Back. Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress. May 05, 2022 | PDF Version - 80% year-over-year revenue growth in Q1 2022 - Achieved all Q1 2022 ELEVATE! milestones - Strong balance sheet with $216.5 million in cash, cash equivalents, and …